Latest Breaking News On - Recardio inc - Page 1 : comparemela.com

BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia

12.07.2022 - SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) - BioCardia, Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary .

Peter altmanMaxim groupBiocardia incRecardio incPharmaceuticals incMesoblast limitedLate stage advancementsHeart failure therapeuticsClick here

Recardio s Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesSan franciscoRecardio incWorld congressEfficacy studyDutogliptinin combinationLatebreaker sessionAcute heart failurePrincipal investigator dirkMedical universityMyocardial infarctionGlobe newswireHeart failure

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoRecardio incWorld congressWorld congress on acute heart failureAcute myocardial infarctionLatebreaker sessionAcute heart failureEfficacy studyDutogliptinin combinationPrincipal investigator dirkMedical universityMyocardial infarctionRelease servicePositive phase

Recardio s Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid

Recardio s Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Recardio s Phase 2 Results Will Be Presented as Latebreaker at World Congress on Heart Failure 2022

Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction will be presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congre.

United statesSan franciscoRecardio incWorld congressWorld congress on acute heart failureAcute myocardial infarctionLatebreaker sessionAcute heart failureEfficacy studyDutogliptinin combinationHeart failurePrincipal investigator dirkMedical universityMyocardial infarctionRelease serviceWill be presented